Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04486833
Title TUSC2-nanoparticles (GPX-001) and Osimertinib in Patients With Stage IV Lung Cancer Who Progressed on Osimertinib Alone (Acclaim-1)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Genprex, Inc.
Indications

lung non-small cell carcinoma

Therapies

Osimertinib + Quaratusugene Ozeplasmid

Osimertinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.